PASG - Neurology-Focused Passage Bio Reveals Initial Data From Dementia Study Outlines Strategic Priorities | Benzinga
Passage Bio Inc (NASDAQ: PASG) announced initial safety and biomarker data from three Cohort 1 patients in the ongoing global Phase 1/2 upliFT-D clinical trial evaluating PBFT02, an adeno-associated virus (AAV)-delivery gene therapy for frontotemporal dementia (FTD) with granulin (GRN) mutations.
FTD is a form of early-onset dementia (memory loss).
- Dose 1 of PBFT02 was generally well-tolerated in patients 2 and 3, who received an enhanced steroid regimen following protocol amendment.
- Patient 1 received a low level of immunosuppression and experienced two SAEs that were both asymptomatic and ...